Clinical trials

Publishing & Design
Archive

APGOT own trials

APGOT-OV1 (VIP)

GO TO LINK

Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer

  • ClinicalTrials.gov ID
  • NCT03188159
  • Sponsor
  • National University Hospital, Singapore
  • Information Provided By
  • National University Hospital, Singapore (Responsible Party)
  • Last Update Posted
  • 29 Mar 2018
  • Current Status
  • Closed

Pre Screening

  • Platinum resistant/refractory primary peritoneal, fallopian tube or ovarian cancer
  • Serous histology
  • High-grade disease

Treatmenu phase

  • IV vinorelbine (25mg/m D1, D8 in 3 week cycle)

Follow-up

  • 1 endpoint : RR
  • 2 endpoint : PFS
  • Molecular Classifier
  • C5 subtype
  • CA125 and tumour scan every two cycles
  • Hypothesis : Vinorelbine provides a targeted approach for C5 HGSC-RR ≥ 30% in C5 HGSOC patients
  • Stage 1 : Aim 10 patients, seeking initial response in ≥ 2
  • Stage 2 : 19 patients 80% power of rejecting null hypothesis if ≥ 6 pts have responded to vinorelbine

Current Recruitment Status

NCIS, Singapore
55 patients, 3 out of these are C5 subtype(5.45%)
All 3 enrolled on study : 2 PD, 1 SD (GCIG response)
  • PeterMac (PMC)
  • 38 patients : 5 patients with C5 subtype (13.2%)
  • Prince of Wales (PWH)
  • 4 patients, none C5
  • Border Medical Oncology (BMO)
  • 1 patient, none C5
  • Overall
  • 98 patients : 8 patients with C5 subtype (8.2%)

APGOT-OV2 (MOCCA)

GO TO LINK

A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas

  • ClinicalTrials.gov ID
  • NCT03405454
  • Sponsor
  • National University Hospital, Singapore
  • Information Provided By
  • National University Hospital, Singapore (Responsible Party)
  • Last Update Posted
  • 18 May 2018
  • Current Status
  • Closed

APGOT-OV3 (LARA)

GO TO LINK

Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)

  • ClinicalTrials.gov ID
  • NCT04699071
  • Sponsor
  • National University Hospital, Singapore
  • Information Provided By
  • National University Hospital, Singapore (Responsible Party)
  • Last Update Posted
  • 21 Oct 2021
  • Current Status
  • Closed

APGOT-OV4 (OPEB-01)

GO TO LINK

Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer

  • ClinicalTrials.gov ID
  • NCT04361370
  • Sponsor
  • Yonsei University, Korea
  • Information Provided By
  • Yonsei University (Responsible Party)
  • Last Update Posted
  • 19 Apr 2021
  • Current Status
  • Closed, Published

APGOT-OV6 (OPERA)

GO TO LINK

Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

  • ClinicalTrials.gov ID
  • NCT05407584
  • Sponsor
  • Yonsei University, Korea
  • Information Provided By
  • Yonsei University (Responsible Party)
  • Last Update Posted
  • 24 May 2023
  • Current Status
  • Closed

APGOT-OV7 (DOVE)

GO TO LINK

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-ov7/​ ENGOT-ov80 Study) (DOVE)

  • ClinicalTrials.gov ID
  • NCT06023862
  • Sponsor
  • Yonsei University, Korea
  • Information Provided by
  • JUNGYUN LEE, Yonsei University (Responsible Party)
  • Last Update Posted
  • 05 Sep 2023
  • Current Status
  • Recruiting

APGOT-OV11 (SOCCER-P)

GO TO LINK

Secondary Cytoreductive Surgery in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance (SOCCER-P)

  • ClinicalTrials.gov ID
  • NCT05704621
  • Sponsor
  • KGOG GROUP
  • Information Provided By
  • KGOG GROUP
  • Last Update Posted
  • April 2024